Clinical Trial Update: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP [Phase 2, Phase 3]

View source ↗

Summary

The MONICA-SC trial evaluating Blisibimod (A-623) for Immune Thrombocytopenic Purpura/Idiopathic Thrombocytopenic Purpura has been withdrawn from Phase 2/3 deve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenic Purpura

Drugs mentioned

• blisibimod (blisibimod)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura | Phase 2, Phase 3 | Status: WITHDRAWN